文献速递银屑病与炎症性皮肤病

新型卡泊三醇/二丙酸倍他米松乳膏治疗银屑病的随机3期试验

Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-08-25

一项在三个欧洲国家开展的多中心、随机、研究者盲法、活性和赋形剂对照的3期试验,纳入490例轻中度银屑病患者,每日一次外用8周。结果显示CAL/BDP PAD-cream的mPASI较基线平均改善67.5%,优于赋形剂(11.7%,p<0.0001),非劣于CAL/BDP凝胶(63.5%);PGA治疗成功率50.7%,优于赋形剂(6.1%,p<0.0001)且显著高于CAL/BDP凝胶(42.7%,p=0.0442)。

要点

  • CAL/BDP PAD-cream每日一次外用8周,mPASI较基线平均改善67.5%,优于赋形剂,非劣于CAL/BDP凝胶。
  • PGA治疗成功率CAL/BDP PAD-cream为50.7%,显著高于CAL/BDP凝胶的42.7%(p=0.0442)。
  • 患者报告的治疗便利性评分CAL/BDP PAD-cream优于CAL/BDP凝胶(p<0.0001),DLQI改善也显著更优。

核心结论

  • CAL/BDP PAD-cream是一种新型外用银屑病治疗药物,具有高疗效和良好安全性,并具有更优的患者报告治疗便利性。

研究设计与样本

  • 3期、多中心、随机、研究者盲法、活性和赋形剂对照试验,在三个欧洲国家纳入490例根据PGA量表评估为轻中度银屑病的患者。
  • 产品每日一次外用,持续8周。

主要发现

  • 第8周mPASI较基线平均变化百分比:CAL/BDP PAD-cream组67.5% vs 赋形剂组11.7%(p<0.0001),CAL/BDP PAD-cream非劣于CAL/BDP凝胶组63.5%。
  • 第8周达到PGA治疗成功(至少两步改善至清除或几乎清除)的患者比例:CAL/BDP PAD-cream组50.7% vs 赋形剂组6.1%(p<0.0001),CAL/BDP PAD-cream组显著高于CAL/BDP凝胶组42.7%(p=0.0442)。
  • 第8周患者报告银屑病治疗便利性评分(PTCS):CAL/BDP PAD-cream优于CAL/BDP凝胶(p<0.0001)。
  • 第8周DLQI较基线平均变化:CAL/BDP PAD-cream组改善显著大于赋形剂组(p<0.0001)和CAL/BDP凝胶组(p=0.0110)。
  • 试验期间安全性评估显示CAL/BDP PAD-cream耐受性良好。

关键数值与推荐

  • 主要终点为第8周mPASI较基线的变化百分比。
  • PGA治疗成功定义为至少两步改善至清除或几乎清除。

临床怎么用

  • 对于轻中度银屑病,CAL/BDP PAD-cream每日一次外用8周可显著改善mPASI和PGA治疗成功率,且患者报告治疗便利性优于CAL/BDP凝胶。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The fixed dose combination of calcipotriene (CAL) and betamethasone dipropionate (BDP) is a well-established topical treatment option for psoriasis based on strong scientific rationale for the single agents having complementary efficacy and safety. CAL/BDP PAD-cream is an easily spreadable cream based on PAD Technology™, an innovative formulation and drug delivery system. OBJECTIVES AND METHODS: A Phase 3, multicentre, randomized, investigator-blind, active and vehicle-controlled trial enrolling 490 patients with mild to moderate psoriasis according to the Physician Global Assessment (PGA) scale was conducted in three European countries. Products were applied once daily for 8 weeks. The aim of the trial was to evaluate the efficacy and safety of CAL/BDP PAD-cream as well as treatment acceptability compared to CAL/BDP gel and PAD-cream vehicle. Primary endpoint was percentage change in modified Psoriasis Area and Severity Index (mPASI) from baseline to Week 8. RESULTS: The percentage mean change from baseline to Week 8 in mPASI for CAL/BDP PAD-cream (67.5%) was superior compared to PAD-cream vehicle (11.7%; p < 0.0001) and non-inferior to CAL/BDP gel (63.5%). The proportion of patients achieving PGA treatment success (at least two-step improvement to clear or almost clear) after 8 weeks was superior for CAL/BDP PAD-cream (50.7%) compared to PAD-cream vehicle (6.1%, p < 0.0001) and statistically significantly greater than CAL/BDP gel (42.7%, p = 0.0442). Patient-reported psoriasis treatment convenience score (PTCS) for CAL/BDP PAD-cream was rated superior to CAL/BDP gel at Week 8 (p < 0.0001) and the mean change in DLQI from baseline to Week 8 improved statistically significantly more in the CAL/BDP PAD-cream group compared to both PAD-cream vehicle (p < 0.0001) and CAL/BDP gel (p = 0.0110). Safety assessments during the trial demonstrated that CAL/BDP PAD-cream was well-tolerated. CONCLUSION: CAL/BDP PAD-cream is a novel topical treatment of psoriasis that has a high efficacy and a favourable safety profile combined with a superior patient-reported treatment convenience.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Pinter A, Reich A, Arenberger P, et al. Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2023. PMID: 37432045. doi:10.1111/jdv.19330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。